FZD3: A Potential Drug Target and Biomarker (G7976)

Target Name: FZD3

NCBI ID: G7976

FZD3

FZD3: A Potential Drug Target and Biomarker

Fuzorin-3 (FZD3) is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the cell cycle and has been implicated in a number of cellular processes, including cell growth, differentiation, and the regulation of cell survival. In recent years, researchers have become increasingly interested in studying FZD3 as a potential drug target and biomarker.

The protein encoded by the FZD3 gene is composed of 116 amino acids and has a calculated molecular mass of 13.9 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and gastrointestinal tract. FZD3 has been shown to play a role in the regulation of cell cycle progression, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

One of the most promising aspects of FZD3 is its potential as a drug target. Researchers have identified several potential binding sites on FZD3 that could be targeted by small molecules. These sites include the N-terminus, the catalytic domain, and the C-terminus. In addition, FZD3 has been shown to interact with a variety of molecules, including the transcription factor p53 and the protein kinase A尾1. These interactions suggest that FZD3 could be a useful target for the development of new therapeutic agents.

In addition to its potential as a drug target, FZD3 has also been shown to be a potential biomarker. The expression of FZD3 has been shown to be regulated by a variety of factors, including DNA methylation, histone modifications, and intracellular signaling pathways. These factors may play a role in the regulation of FZD3 function and could be potential targets for diagnostic tests.

FZD3 has also been shown to be involved in the regulation of cellular processes that are important for human health and disease. For example, studies have shown that FZD3 is involved in the regulation of cell proliferation and has been implicated in the development of cancer. In addition, FZD3 has been shown to be involved in the regulation of cell death, which is important for the maintenance of tissue homeostasis and the regulation of physiological processes such as breathing and heart rate.

Overall, FZD3 is a protein that has great potential as a drug target and biomarker. Its unique structure and multiple functions make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of FZD3 in cellular processes and its potential as a therapeutic agent.

Protein Name: Frizzled Class Receptor 3

Functions: Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. Activation by Wnt5A stimulates PKC activity via a G-protein-dependent mechanism. Involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Plays a role in controlling early axon growth and guidance processes necessary for the formation of a subset of central and peripheral major fiber tracts. Required for the development of major fiber tracts in the central nervous system, including: the anterior commissure, the corpus callosum, the thalamocortical, corticothalamic and nigrostriatal tracts, the corticospinal tract, the fasciculus retroflexus, the mammillothalamic tract, the medial lemniscus, and ascending fiber tracts from the spinal cord to the brain. In the peripheral nervous system, controls axon growth in distinct populations of cranial and spinal motor neurons, including the facial branchimotor nerve, the hypoglossal nerve, the phrenic nerve, and motor nerves innervating dorsal limbs. Involved in the migration of cranial neural crest cells. May also be implicated in the transmission of sensory information from the trunk and limbs to the brain. Controls commissural sensory axons guidance after midline crossing along the anterior-posterior axis in the developing spinal cord in a Wnt-dependent signaling pathway. Together with FZD6, is involved in the neural tube closure and plays a role in the regulation of the establishment of planar cell polarity (PCP), particularly in the orientation of asymmetric bundles of stereocilia on the apical faces of a subset of auditory and vestibular sensory cells located in the inner ear. Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle in a beta-catenin-dependent manner (By similarity)

The "FZD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FZD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets